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http:WHAT THIS PAPER ADDS
Without device removal aortic endograft infection is fatal, but abdominal endograft explantation carries a 30%
30-daymortality. Extensionwith newdevices or sac drainage are useful temporisingmeasures, but are not curative.Objectives: The management of thoracic and abdominal aortic endograft infection is complex and associated
with high mortality. Cases are rare: a recent systematic review identiﬁed 117 reported cases; the largest reported
series comprises 12 infected endografts.
Methods: We report 22 consecutive patients with infected abdominal or thoracic aortic endovascular devices
implanted from 1998 to 2012. Management included extension with new devices, aneurysm sac drainage of pus/
irrigation with antibiotics, endograft explantation, and axillo-(bi)femoral reconstruction.
Results: Twenty-two patients (16 men) were identiﬁed. Median age was 71 years (range, 43e88 years). Index
devices were infra-renal endovascular repair (n ¼ 13), and thoracic endovascular repair (n ¼ 9) all for aneurysmal
or pseudoaneurysmal disease. Seven (32%) had prior aortic surgery. Follow-up was complete in all cases; in
survivors follow-up was a median of 29 (range, 12e45) months. The mortality from explantation of ten infra-renal
devices was 1/10 (10%) on-table and a further 2/10 (20%) within 30 days. Device retention led to disease
progression and death in all patients with infected endografts. Sac drainage/irrigation provided only temporary
control of sepsis. Device extension can treat rupture, but additional devices became infected.
Conclusion: Abdominal endograft explantation is high risk but may be curative. Appropriate selection of patients
for infected endograft explantation remains a major challenge.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Since the initial reports of endovascular devices their use
has increased dramatically in both the infra-renal and
thoracic aorta.1,2 Endograft infection was ﬁrst reported in
1993 and now affects approximately 1% of implantations.3e
8 Infection is likely to remain a signiﬁcant problem, but
clinical reports are limited.6 A systematic review identiﬁed
117 published cases (34 thoracic, 83 abdominal) with many
individual case reports, making comparison of different
management options difﬁcult.4,6,7,9 To the best of our
knowledge the largest aortic endograft explantation series
comprises only nine patients.5
Traditionally endograft infection has been managed by
removal of all foreign material with debridement of infectedresponding author. O.T.A. Lyons, Vascular Surgery Unit, Guy’s & St
s’ NHS Foundation Trust, London SE1 7EH, United Kingdom.
il address: oliver.lyons@kcl.ac.uk (O.T.A. Lyons).
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//dx.doi.org/10.1016/j.ejvs.2013.04.021tissue followed by arterial reconstruction, either in situ
using biological conduit or extra-anatomically using pros-
thetic graft, followed by prolonged antibiotic therapy.4,10
Aortic endograft infection presents particular difﬁculties
owing to the high risk of major aortic surgery, and the
challenge of reconstructing the arterial supply in patients
who may be poor candidates for open surgery. Enteric
ﬁstulae can re-infect the ﬁeld.11 Endograft design poses
particular problems as none are intended to be removable
and bare proximal stents may become embedded in the
aortic wall, complicating explantation.12 Consequently the
outcome of infected abdominal and thoracic endografts is
poor, with estimated overall short- to medium-term survival
of 30% and 65% respectively.4 Conservative management of
endograft infection without device removal has been
described, with variable results.6,9,13,14 Removal of infected
endografts is associated with high short-term mortality of
approximately 20e30% and 47% for abdominal and thoracic
devices respectively.4,6
This article describes our experience with management
of infected abdominal and thoracic devices with sac
O.T.A. Lyons et al. 307drainage, extension with new devices, or explantation with
extra-anatomical reconstruction.
MATERIALS AND METHODS
Patients with endograft infection were retrospectively
identiﬁed from a prospectively maintained consecutive
database of devices implanted from 1998 to 2012.The ‘index’
device refers to the ﬁrst aortic endograft deployed in the
aorta. Cases were reviewed for prior aortic procedures,
endografts deployed, and aetiology of endograft infection.
Mycotic aneurysms and aorto-enteric ﬁstulae were investi-
gated and diagnosed as described previously.11 Aortic
endograft infection was diagnosed with a combination of
radiological evidence (air within the sac on computed to-
mography [CT], aided by positron emission tomography CT,
or white cell scan in some patients), microbiology (positive
sac or peripheral blood cultures), and clinical evidence of
sepsis. Endografts deployed in ‘infected ﬁelds’ (e.g., mycotic
aneurysm, aortoenteric ﬁstula) were not assumed to be
infected until patients presented with features of infection.
Oesophagogastroscopy and bronchoscopy were performed
to identify aorto-oesophageal, aorto-enteric and aorto-
bronchial ﬁstulae. Fitness for surgery was assessed with
respiratory, cardiac, and renal investigations, and consider-
ation was given to life expectancy from comorbid conditions.
Antibiotics were given to all patients with advice from the
microbiology department.
Explantation method
Our method of explantation of infrarenal devices has been
described in detail elsewhere.12,15 An axillo-(bi)femoral
bypass graft is performed immediately prior to midline
laparotomy with the proximal common femoral arteries
clamped to prevent competitive ﬂow from the native ar-
teries. At laparotomy the sac is opened and the graft main
body clamped to allow retrieval of the iliac limbs and distal
control. A Foley catheter (with a 30-ml balloon) is passed
proximally via the contralateral iliac limb and inﬂated within
the thoracic aorta to allow displacement of the proximal
(including supra-renal) ﬁxation with a metal sucker. Occa-
sionally, a supra-renal clamp is used for proximal control.
The endograft is collapsed digitally and pulled distally, and
the stump of infra-renal aorta is oversewn with a layer of
interrupted mattress 2-3/0 prolene followed by two
continuous layers of 2-3/0 prolene. Omentum is sutured
over the open aneurysm sac after extensive debridement of
infected tissue, and drains are placed for irrigation of the
aortic stump.
Sac irrigation and washout
Following exclusion of endoleak with a contrast-enhanced
CT scan, pigtail drains are placed in the aneurysm sac un-
der CT guidance. Antibiotics or saline are instilled through
the drains regularly until the patient’s temperature, white
cell count and C-reactive protein are normal (usually 5e7
days). Two drains may be placed, allowing concomitant
irrigation and drainage of the sac. Irrigation failed in onepatient with aorto-bronchial ﬁstula as instillation produced
coughing.Extension with further devices
Devices are placed proximal and/or distal to the infected
device to extend coverage into non-infected aorta (Fig. 1).
One renal artery was intentionally covered when this was
the only option to obtain a proximal landing zone.
RESULTS
Twenty-two patients (16 men) were identiﬁed with infected
endografts (9 thoracic, 13 abdominal) deployed between
1998 and 2012. Indications for use of the index device are
given in Table 1. Only one thoracic and six abdominal
stentgrafts were inserted for non-infected, non-salvage in-
dications. Seven (32%) index devices were deployed for
complications following prior open aortic surgery. During the
study period seven ﬁstulaewere treatedwith endografts, and
six (86%) subsequently presented with device infection.
Devices used were Gore TAG, TX2, Talent, Cook Zenith, Low
Proﬁle, Aneuryx, Medtronic, and aortic cuffs. Index devices in
18 out of 22 patients (82%) were deployed in our tertiary
centre; seven patients (32%) after having been referred from
elsewhere (e.g., with aorto-enteric ﬁstula). Four patients
(18%) were referred to us following deployment and
subsequent diagnosis of infection elsewhere. Follow-up from
presentation with endograft infection was a median of 29
(range, 12e45) months in survivors.
The median age at presentation with infection was 71
(range, 43e88) years. Signiﬁcant comorbidities included
hypertension in 12 (55%), pulmonary disease in seven
(32%), ischaemic heart disease in eight (36%), diabetes in
two (9%), prior surgery for cancer in eight (36%), blood
dyscrasia in two (9%) patients, and congenital aortic
coarctation and pneumothorax with pleuradhesis in one
(5%), monosomy chromosome 7 in one (5%), and pan-
hypopituitarism (treated with steroids) following hypophy-
sectomy in one (5%) patient.
Presentation with infection was a median of 5 (range, 0e
51) months after the original index deployment. Presenta-
tion was with fever in 13 (59%), leucocytosis
>11  109 cellsl1 in 13 (59%), chest or abdominal pain in
12 (55%), rigors in nine (41%), bleeding in ten (45%), frank
rupture in seven (32%), and anorexia in six (27%) patients.
Anorexia and cachexia were prominent in patients with a
prolonged duration of infection prior to diagnosis.
The major risk factors for device infection included sepsis
post deployment in 11 (50%), primarily infected pathology
in 11 (50%), re-intervention in six (27%), and ﬁstula in ﬁve
(23%) patients. Patients with an index device deployed in
primarily infected pathology were more likely to present
with infection within 3 months of deployment (p ¼ .009,
Fisher’s exact test).
Causative organisms were cultured from the endograft,
blood, or sac aspirate in only 12 (55%) patients, probably
due to prior antibiotic use. Single isolates were Escherichia
coli (n ¼ 3 patients), Staphylococcus aureus (n ¼ 1),
Figure 1. (AeD) Patient 22. (A) Contained rupture of thoracic aorta after oesophagectomy, managed emergently with an endograft (B). He
re-presented 10 weeks later with haemoptysis (C) showing complete radial expansion of the index device and proximal and distal
pseudoaneurysmal disease progression (arrows). He was treated as an emergency with proximal and distal extension (D). He died from
visceral emboli. (E) An explanted infra-renal device (with supra-renal ﬁxation embedded in the aortic wall).
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bacterium (n ¼ 1). Of 5 (23%) cases that grew mixed or-
ganisms, three were combinations of Pseudomonas with
either E. coli and S. aureus (n ¼ 1), Klebsiella (n ¼ 1), or
coagulase-negative Staphylococcus (n ¼ 1). One case was
Enterococcus with Candida; one was Streptococcus milleri
with Candida.Management and perioperative mortality
All patients received antibiotics with specialist advice. Nar-
row spectrum antimicrobials were used where the causativeorganism and sensitivity proﬁle was known. Broad-
spectrum therapy was given to those with no growth.
Abdominal endografts. The device was not explanted in
three patients with infra-renal devices because they were
unﬁt for major surgery; all died due to progression of their
aortic disease. In patient 11 two drains were placed in the
sac for irrigation (pus was aspirated). Patient 12 was not ﬁt
for the thoraco-laparotomy required for explantation and
was planned for re-lining, but died from mesenteric
ischaemia while waiting for a custom-made fenestrated
device to be manufactured.
Table 1. Patients, index indications, management, follow-up, and outcomes.
No. Age (years) Indication for index device Re-interventions
prior to presentation
with infection
Management of
index device infection
Follow-up
from infection
presentation
(months)
Cause of death
Infected infra-renal aortic devices
1a 66 Elective EVAR; subsequent discitis, psoas
collection
e Explant þ AxFem 27, alive e
2a,b 69 Elective EVAR (right iliac occlusion,
unplanned fem-fem crossover, paraplegia)
e Explant þ AxFem 29, alive e
3b 78 Elective EVAR Limb extension,
embolisation
type 2 endoleak, open
taping of iliac limbs
Explant þ AxBifem 28, alive e
4b,c 78 Aorto-enteric ﬁstula following
elective open infra-renal aneurysm repair
e Explant þ AxBifem 12, alive e
5a,b 83 Elective EVAR e Explant þ AxBifem 68, dead Bronchopneumonia, COAD
6c 82 Elective EVAR Right limb occlusion
and type II endoleak:
femefem crossover and
open ligation right IIA
Explant þ AxBifem 0, dead Intra-operative cardiac arrest;
acute kidney injury,
respiratory failure
7a,b 86 Elective EVAR; re-exploration
of bilateral groin haematomas
e Explant þ AxBifem 16, dead Coagulopathy, iatrogenic liver puncture
8 75 Auto-uniliac for ruptured iliac aneurysm Coiling of internal iliac artery Explant þ AxBifem 0, dead Intra-operative haemorrhage
9a,b 71 Ruptured mycotic infra-renal aneurysm (renals
covered during top cap recapture; device pulled
down with wire snared over bifurcation)
e Explant þ AxBifem 4, dead Metastatic cancer
10b 68 Urgent for tender AAA Right popliteal
embolectomy,
left limb extension
Drain, Explant þ AxBifem 1, dead Acute kidney injury and
respiratory failure
11b 80 Expanding mycotic aneurysm e Drains, Abx, embolisation
of ruptured visceral
mycotic aneurysms
0, dead Sepsis and intra-abdominal
haemorrhage (visceral
mycotic aneurysms)
12 69 Elective mycotic infra-renal aneurysm Thrombectomy and
BMS for thrombosed
right limb, later
kissing balloon
angioplasty
Abx (awaiting fenestrated
device for relining)
3, dead Ischaemic bowel
(pseudoaneurysm at
origin visceral arteries)
13b 88 Aorto-enteric ﬁstula following open repair e Proximal extension
cuff, Abx
5, dead Chronic sepsis,
pulmonary oedema
Infected thoracic aortic devices
14b 43 Coarctation repair age 20 years, pleuradhesis,
failed open repair of pseudoaneurysmal
degeneration of graft (LCCA bypass placed)
e Drain
Abx(exsanguinated prior
to explantation)
15, dead Aorto-bronchial haemorrhage
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Table 1-continued
No. Age (years) Indication for index device Re-interventions
prior to presentation
with infection
Management of
index device infection
Follow-up
from infection
presentation
(months)
Cause of death
15b,c 68 Coronary bypass grafts followed by open repair
of type III thoracoabdominal aneurysm, with
infected pseudoaneurysm at proximal
anastomosis
e Abx, decortication
bovine patch, left lower
lobectomy, thoracic
window
45, dead Aorto-bronchial haemorrhage
16b 72 Elective thoracic aneurysm (following carotid
crossover)
LSCA chimney stent
for symptoms of hand
ischaemia
TEVAR þ drain 10, dead Aorto-bronchial haemorrhage
17b,c 75 Infected pseudoaneurysm following open
thoracoabdominal aneurysm repair
e Abx 1, dead Aorto-enteric haemorrhage
18b,c 63 Aorto-oesophageal ﬁstula following open repair
thoracic transection
e Abx 13, dead Aorto-oesophageal haemorrhage
19b,c 69 Aorto-oesophageal ﬁstula e TEVAR 1, dead Multi-organ failure
20b 69 Cutaneous-left subclavian aneurysm ﬁstula
following radiotherapy
e Abx 5, dead Aorto-cutaneous haemorrhage
21b 75 Infected pseudoaneurysm following open repair
thoracic aortic dissection
e Abx 53, dead Aorto-oesophageal haemorrhage
22b,c 59 Mycotic thoracic aneurysm following
oesophagectomy
e TEVAR þ drain 3, dead Ischaemic bowel, kidneys (embolic)
Note. Follow-up refers to time from presentation with infection (not initial deployment). Age refers to time of presentation with infection. AAA ¼ abdominal aortic aneurysm;
Abx ¼ antibiotics/antifungals; BMS ¼ bare metal stent; COAD ¼ chronic obstructive airway disease; EVAR ¼ infra-renal stentgraft; IIA ¼ internal iliac artery; LCCA ¼ left common
carotid artery; LSCA ¼ left subclavian artery; TEVAR ¼ thoracic stentgraft.
a Osteomyelitis/discitis.
b Local deployment of index stentgraft.
c Referrals from other centres prior to index device deployment.
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O.T.A. Lyons et al. 311Early outcome after explantation. Ten (45%) devices were
explanted from the infra-renal aorta of men with a median
age of 78 (range, 68e86) years. Patient 6 suffered cardiac
arrest in surgery (the aorta was found to have ruptured),
and died with renal and respiratory failure in the intensive
care unit. Patient 8 died during surgery as a result of un-
controllable haemorrhage from friable iliac arteries. All
renal arteries were preserved despite supra-renal ﬁxation.
Patient 10 required early thrombectomy of the bypass graft,
and died with renal and respiratory failure. In total, three
patients (30%) required ﬁltration, four (40%) contracted
pneumonia, and one (10%) required re-laparotomies for
sepsis owing to a persistent duodenal ﬁstula. Overall 30-day
mortality was three (30%).
Medium-term outcome. There were no re-operations for
aortic bleeding and no incidence of blowout of the aortic
stump. Patient 4 had successful radiological drainage of an
abdominal collection and bypass graft thrombectomy at 1
year. Patient 9 died at 3 months from metastatic cancer.
Patient 5 was found to have osteomyelitis and collapse of
L4, and required a corpectomy and cage reconstruction at 4
months, complicated by an iliac vein tear. He subsequently
developed infection of the bypass graft that resulted in an
above-knee amputation. Patient 7 died at another centre at
16 months (aged 87 years) from coagulopathy and iatro-
genic puncture of the liver during an attempt to drain an
abdominal collection.
Thoracic endograft infection. The device was not explanted
in nine thoracic patients who were unﬁt or refused
explantation, and seven (78%) had died at 24 months. Pa-
tient 14 exsanguinated from an aortobronchial ﬁstula while
explantation was being planned. He required a pneumo-
nectomy as a previous attempt at open repair failed owing
to adhesions following prior pleuradesis for spontaneous
pneumothorax.
New endograft extensions were used in three thoracic
cases as a life saving temporising measure for haemorrhage
or pseudoaneurysm progression (patients 16, 19, and 22).
Patients 19 and 22 died 1 month and 1 day later. Patient 16
had presented with massive bleeding via an aorto-bronchial
ﬁstuladextension was successful in preventing recurrent
bleeding for 9 months until disease recurred.
Percutaneous drainage of the aneurysm sac was per-
formed in patients 14, 16, and 22, and appeared useful in
reducing systemic sepsis. In combination with lifelong an-
tibiotics this produced a moderate outcome in some pa-
tients, but infection eventually progressed in all patients.
Patient 15 received an index thoracic endograft for
infected pseudoaneurysmal degeneration/rupture at the
proximal anastomosis of an open type III thoracoabdominal
aneurysm repair.16 Following endograft infection he was
managed with antibiotics, but suffered disabling daily hae-
moptypsis due to an aorto-bronchial ﬁstula, and underwent
left lower lobectomy and bovine patch interposition
between the graft and left upper lobe at 40 months.
Initially this was successful but pleural sepsis subsequentlyrequired creation of a thoracic window. Haemoptysis
recurred and he died at 45 months.DISCUSSION
Infection is a rare complication of endovascular treatment
and there is no good evidence to guide management.3,4 To
the best of our knowledge our data represent the largest
consecutive series of infected endografts and of explanted
devices. We show promising midterm results from explan-
tation of infected abdominal endografts but the series is too
small and heterogeneous to allow for statistical evaluation.
No patient died as a result of aortic disease after the
infected device was removed. Because of the rarity of these
cases it is difﬁcult to ﬁnd suitable controls with which these
results can be compared, but crude comparison with the
un-explanted cases and data from the literature suggests
that explantation may avoid the problems of aortic
bleeding, sepsis, and septic emboli associated with device
retention. In this series all patients (abdominal and
thoracic) who did not have their endografts explanted died
of aortic disease progression. The 30-day mortality of 30%
from endograft explantation is comparable with that ach-
ieved by others.4,7,17e19 Laser et al.5 reported 22% mortality
in nine patients, three of whom had aortoenteric ﬁstulae.
Phade et al.19 achieved 17% mortality in six patients.
Following a questionnaire survey sent to multiple centres
Ducasse et al.7 reported 14% mortality with surgical treat-
ment and 36% with conservative treatment. These authors
also suggested an improved mortality after explantation
compared with conservative therapy.7 Extra-anatomical
reconstruction using axillo(bi)femoral bypass was per-
formed before explantation of the abdominal device to
reduce operative time and maintain perfusion of the limbs
during explantation, but was associated with a 30%
complication rate during the study period.20 A recent sys-
tematic review suggested a lower mortality with in situ
reconstruction (22%) than extra-anatomic bypass (31%) in
treating abdominal infections.4,7 In situ options include
reconstruction using femoral vein or spiralled long saphe-
nous vein, rifampicin-soaked graft, silver-coated graft, allo-
graft, or bovine pericardium.8,9,18,21e27
Mortality from management of thoracic aortic endograft
infection without explantation is reported as 70%, but in
this series with longer and complete follow-up the mortality
was 100% (and was due to their aortic disease).4,6,14,28
Extension with further devices was used in salvage situa-
tions to prevent immediate death from rupture. While
temporary control was achieved this failed in the relatively
short term.4,29e31 Drainage of pus and irrigation of the sac
improved systemic sepsis but did not prevent progression
to death. Reconstruction following thoracic endograft
explantation is challenging owing to anatomical constraints
and the need for higher ﬂow rates through the conduit. No
thoracic devices were explanted in this series.32,33 Recon-
struction with homograft is possible; alternatively, an
ascending aortic to infrarenal aortic extra-anatomic bypass
may be performed.26,33e35
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infected ﬁeld, such as a mycotic aneurysm, infected pseu-
doaneurysm or aortoenteric ﬁstula suggests that endovas-
cular treatment is only a temporising measure. We have
previously demonstrated acceptable medium-term survival
with endovascular repair in infected ﬁelds if an organism can
be identiﬁed and treated with appropriate antibiotics,
although there is a high risk of eventual failurewith ﬁstulae.11
In this series we have presented survival following presen-
tation with infection, not following deployment. Six out of
seven ﬁstulae treated with endografts in the study period
subsequently presented with infection, but several patients
had devices successfully implanted in infected ﬁelds for
extended periods before problems occurred. Endovascular
repair remains an important option in those with an infected
ﬁeld who are unﬁt for open surgical repair (particularly in the
setting of active haemorrhage) or who have complications of
a prior open repair.11,36e38
In the present series, only four EVAR and one thoracic
endovascular repair devices was implanted at our centre for
non-infected, non-salvage indications. Patients with infec-
ted endografts could have remained undiagnosed, been
referred elsewhere, or died out of hospital. This supports
the estimation of others who have suggested infection rates
in the region of 1%.4,9,24
Most authors have identiﬁed Staphylococcus and Strep-
tococcus spp. in endograft infection as the most common
causative organisms, with S. aureus being the single most
signiﬁcant pathogen involved.4,6,7 In this series Gram-
negative organisms (e.g., E. coli and Enterococcus) were
also identiﬁed, and have previously been reported alongwith
Candida.4e6 Four out of six (67%) E. coli or Enterococcus
isolates were associatedwith abdominal endografts, while 2/
6 (33%, patients 15 and 18) followed thoracic endovascular
repair for proximal pseudoaneurysms after thoracolapar-
otomy. Antibiotic/antifungal therapy was determined on a
case-by-case basis, guided by culture results. Broad-
spectrum therapy was administered when the causative or-
ganism could not be identiﬁed, which occurred in half these
patients and in 18e50% of reported cases.5,6 Percutaneous
sac drainage can be useful in obtaining diagnostic cul-
tures.39,40 Antibiotics were continued long-term for osteo-
myelitis and indeﬁnitely (with variable compliance) when the
endograft remained in situ. In-dwelling central venous
catheters were used for outpatient intravenous therapy
when there was no oral alternative.
Several risk factors for endograft infection have been
suggested.4,6 Infection increasingly follows endovascular
salvage of complications of open aortic surgery, which
substantially complicates management.41 In the present
series approximately half the cases had a primarily infected
aortic problem, such as a mycotic aneurysm or an aor-
toenteric/cutaneous ﬁstula, and they presented with
endograft infection earlier than those with uninfected pa-
thology. Half of this series had a period of sepsis following
index device deployment that may have seeded bacteria in
the aneurysm sac/thrombus. The re-intervention rate
following index deployment and prior to presentation withinfection was 27%, suggesting that inoculation during re-
intervention is important.6 These endografts were inser-
ted in multiple units and the re-intervention rate in the non-
infected cases is not available for comparison, but is likely to
be much lower.42 Some of these re-interventions are no
longer considered necessary and so this problem may
decrease with time. One of our patients was taking steroids,
which may have contributed to a reduced ability to deal
with infection.6
There are several limitations to the current study. It is
small but the majority of patients were followed until death.
The study group is heterogeneous with infected and non-
infected primary pathologies, but there is no evidence that
they subsequently behave differently once the device is
infected. Diagnosis of infected aneurysms can be challenging
and it is possible that some aneurysms that were thought to
be uninfected were in fact infected at the index deploy-
ment.11 Selection of patients for surgery was based on pa-
tient ﬁtness, thus making it difﬁcult to draw any conclusions
about which patients might beneﬁt from explantation.
Conservative temporising measures remain the mainstay of
therapy in patients unﬁt for explantation, particularly in the
thoracic aorta.
CONCLUSIONS
Explantation of infected abdominal endografts carries a
high early mortality and morbidity, and appropriate selec-
tion of patients for such a high-risk procedure remains a
major challenge, but explantation can result in cure of aortic
endograft infection. Conservative (non-operative) manage-
ment with retention of the infected aortic endograft inev-
itably results in death from disease progression, usually
within two years of presentation with infection.
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